Cargando…

Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis

INTRODUCTION: Biologics used to treat moderate-to-severe plaque psoriasis may cause injection site reactions (ISRs) characterized by erythema, edema, itch, and sometimes pain. The Federal Adverse Event Reporting System (FAERS) is a repository of spontaneous post-marketing reports of adverse events (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grace, Elsie, Goldblum, Orin, Renda, Lisa, Agada, Noah, See, Kyoungah, Leonardi, Craig, Menter, Alan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994575/ https://www.ncbi.nlm.nih.gov/pubmed/31734937 http://dx.doi.org/10.1007/s13555-019-00341-2

Ejemplares similares

Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool
por: Leonardi, Craig, et al.
Publicado: (2021)

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
por: Leonardi, Craig L., et al.
Publicado: (2022)

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
por: Hawkes, Jason E., et al.
Publicado: (2021)

Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
por: Kivelevitch, Dario, et al.
Publicado: (2019)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort
por: Egeberg, Alexander, et al.
Publicado: (2020)

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses
por: Warren, Richard B., et al.
Publicado: (2019)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
por: Liu, Wensheng, et al.
Publicado: (2023)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
por: Paul, Carle, et al.
Publicado: (2017)

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
por: Armstrong, April, et al.
Publicado: (2019)

Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization
por: Armstrong, April W., et al.
Publicado: (2018)

Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy
por: Ravasio, Roberto, et al.
Publicado: (2021)

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Fusaroli, Michele, et al.
Publicado: (2022)

A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2015)

Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2016)

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis
por: Leonardi, C, et al.
Publicado: (2008)

Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH
por: Poulin, Y, et al.
Publicado: (2014)

A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis
por: Haque, Emily K., et al.
Publicado: (2020)

Analysis of Factors Associated with Hiccups Using the FAERS Database
por: Hosoya, Ryuichiro, et al.
Publicado: (2021)

The inside guide to the federal IT market
por: Perera, David, et al.
Publicado: (2012)

The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010
por: Hoffman, Keith B., et al.
Publicado: (2014)

Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
por: Strober, B., et al.
Publicado: (2020)

Erratum to: The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010
por: Hoffman, Keith B., et al.
Publicado: (2014)

Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase(®)
por: Vogel, Ulrich, et al.
Publicado: (2020)

Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database
por: Makunts, Tigran, et al.
Publicado: (2022)

Emerging Therapies for the Treatment of Psoriasis
por: Patel, Mahir, et al.
Publicado: (2012)

Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis
por: A. Foster, Shonda, et al.
Publicado: (2016)

Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies
por: Menter, Alan, et al.
Publicado: (2016)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
por: Blauvelt, Andrew, et al.
Publicado: (2020)

Marketing approval of mogamulizumab: A triumph for glyco-engineering
por: Beck, Alain, et al.
Publicado: (2012)

Drug-loaded erythrocytes: on the road toward marketing approval
por: Bourgeaux, Vanessa, et al.
Publicado: (2016)

Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database
por: Kimura, Goji, et al.
Publicado: (2015)

Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database
por: Madigan, David, et al.
Publicado: (2018)

Analysis of Adverse Reactions of Aspirin in Prophylaxis Medication Based on FAERS Database
por: Ren, Weidong, et al.
Publicado: (2022)

Analysis of Opioid-Related Adverse Events in Japan Using FAERS Database
por: Hirai, Risako, et al.
Publicado: (2023)

Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database
por: Altebainawi, Ali F., et al.
Publicado: (2023)

Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)
por: Papp, K., et al.
Publicado: (2020)

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
por: Kivelevitch, Dario, et al.
Publicado: (2014)

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
por: Deodhar, A., et al.
Publicado: (2019)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_402turkmgrpft85ed12tu3ub2b